The transwell experiments proved that CLDN18-ARHGAP26/42 fusion can promote the ability of paclitaxel to inhibit the invasion and metastasis of GC cells, while these fusions had no significant effect on the invasion and migration ability of GC cells (Fig. 6d, e). Here, CLDN18 is linked to gastric cancer.